Difference between revisions of "Plerixafor (Mozobil)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.mozobil.com/document/Package_Insert.pdf Plerixafor (Mozobil) package insert]</ref><ref>[http://hemonc.org/...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.mozobil.com/document/Package_Insert.pdf Plerixafor (Mozobil) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ | + | Class/mechanism: Mobilizes hematopoetic stem cells by inhibiting the CXCR4 chemokine receptor and blocking its cognate ligand, stromal cell-derived factor-1α (SDF-1α). One function of CXCR4 is to anchor stem cells to the marrow matrix via SDF-1α or other adhesion molecules.<ref name="insert">[http://www.mozobil.com/document/Package_Insert.pdf Plerixafor (Mozobil) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/plerixafor.pdf Plerixafor (Mozobil) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: SC |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.uptodate.com/contents/ | + | *[http://www.uptodate.com/contents/plerixafor-patient-drug-information Plerixafor (Mozobil) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/plerixafor-patient-drug-information Plerixafor (Mozobil) patient drug information (UpToDate)]</ref> |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 03:00, 14 January 2012
General information
Class/mechanism: Mobilizes hematopoetic stem cells by inhibiting the CXCR4 chemokine receptor and blocking its cognate ligand, stromal cell-derived factor-1α (SDF-1α). One function of CXCR4 is to anchor stem cells to the marrow matrix via SDF-1α or other adhesion molecules.[1][2]
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].